Literature DB >> 25245053

microRNA-548l is involved in the migration and invasion of non-small cell lung cancer by targeting the AKT1 signaling pathway.

Caihong Liu1, Huan Yang, Zhijie Xu, Dan Li, Meiyu Zhou, Kui Xiao, Zhihui Shi, Lanyan Zhu, Lifang Yang, Rui Zhou.   

Abstract

PURPOSE: microRNAs (miRNAs) have been documented playing a critical role in cancer development and progression. In this study, we investigated the role of miR-548l in non-small cell lung cancer (NSCLC) migration and invasion.
METHODS: microRNAs microarray analysis was used to detect the differentially expressed miRNAs between various metastatic levels of NSCLC cells and further confirmed by real-time PCR analysis. To facilitate the delineation of the role of selected miR-548l in NSCLC pathology, we detected its expression in 22 NSCLC tissues. Proliferation, apoptosis, invasion and metastasis effects of the miRNA were evaluated using MTT, flow cytometry, wound healing and invasion assay following transfection with mimics and inhibitors. Luciferase assay and Western blot analysis were performed to assess miR-548l binding to AKT1 gene. AKT1 expression in the clinical tissues was evaluated using immunohistochemical staining.
RESULTS: The results showed a negative relationship between miR-548l expression and lymph node metastasis of NSCLC. Functional assays showed that over-expression of miR-548l suppressed NSCLC cell migration and invasion. Luciferase assays confirmed that miR-548l could directly bind to the 3' untranslated region of AKT1. Further data showed that the over-expression of AKT1 could rescue the effects of miR-548l in NSCLC cells, and the miR-548l expression was inversely correlated with AKT1 expression in NSCLC tissues. These results indicated that AKT1 was involved in miR-548l-induced suppression of NSCLC cell migration and invasion.
CONCLUSION: These results suggested that miR-548l may play a causal role through AKT1 in NSCLC invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25245053     DOI: 10.1007/s00432-014-1836-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  25 in total

1.  MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.

Authors:  Ji-Guang Zhang; Jian-Feng Guo; Dong-Lei Liu; Quan Liu; Jian-Jun Wang
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

2.  PTEN inhibition improves wound healing in lung epithelia through changes in cellular mechanics that enhance migration.

Authors:  Cosmin Mihai; Shengying Bao; Ju-Ping Lai; Samir N Ghadiali; Daren L Knoell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-10-28       Impact factor: 5.464

3.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

Review 4.  Understanding the role of tissue degrading enzymes and their inhibitors in development and disease.

Authors:  Tim E Cawston; Amy J Wilson
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-10       Impact factor: 4.098

5.  Decreased miRNA-148a is associated with lymph node metastasis and poor clinical outcomes and functions as a suppressor of tumor metastasis in non-small cell lung cancer.

Authors:  Yong Chen; Lingfeng Min; Xizhi Zhang; Suwei Hu; Buhai Wang; Wei Liu; Rui Wang; Xuewen Gu; Weigan Shen; Houning Lv; Jing Zou; Yuexiang Chen; Xingxiang Xu; Longbang Chen
Journal:  Oncol Rep       Date:  2013-07-09       Impact factor: 3.906

6.  PI3K-dependent GSK3ß(Ser9)-phosphorylation is implicated in the intestinal epithelial cell wound-healing response.

Authors:  Thomas Karrasch; Tanja Spaeth; Brigitte Allard; Christian Jobin
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

7.  Topical insulin accelerates wound healing in diabetes by enhancing the AKT and ERK pathways: a double-blind placebo-controlled clinical trial.

Authors:  Maria H M Lima; Andréa M Caricilli; Lélia L de Abreu; Eliana P Araújo; Fabiana F Pelegrinelli; Ana C P Thirone; Daniela M Tsukumo; Ana Flávia M Pessoa; Marinilce F dos Santos; Maria A de Moraes; José B C Carvalheira; Lício A Velloso; Mario J A Saad
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

8.  7,8-Dihydroxycoumarin inhibits A549 human lung adenocarcinoma cell proliferation by inducing apoptosis via suppression of Akt/NF-κB signaling.

Authors:  Yue Wang; Chang-Feng Li; Li-Ming Pan; Zhong-Li Gao
Journal:  Exp Ther Med       Date:  2013-04-09       Impact factor: 2.447

9.  miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1.

Authors:  Yang Ke; Weiyong Zhao; Jie Xiong; Rubo Cao
Journal:  Biochem Res Int       Date:  2013-05-16

10.  miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2).

Authors:  Heyong Wang; Yingchao Zhu; Mingchuan Zhao; Chunlian Wu; Peng Zhang; Liang Tang; Huijun Zhang; Xiaofeng Chen; Yaoqin Yang; Gentao Liu
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more
  12 in total

1.  Long non-coding RNA GAS5, by up-regulating PRC2 and targeting the promoter methylation of miR-424, suppresses multiple malignant phenotypes of glioma.

Authors:  Chen Jin; Jie Zhao; Zhi-Ping Zhang; Ming Wu; Jian Li; Ge-Lei Xiao; Bo Liu; Yu-Xiang Liao; Jing-Ping Liu
Journal:  J Neurooncol       Date:  2020-05-29       Impact factor: 4.130

Review 2.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

3.  A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma.

Authors:  Yu-Zheng Ge; Ran Wu; Hui Xin; Meng Zhu; Tian-Ze Lu; Hao Liu; Zheng Xu; Peng Yu; You-Cai Zhao; Ming-Hao Li; Zhi-Kai Hu; Yan Zhao; Bing Zhong; Xiao Xu; Liu-Hua Zhou; Lu-Wei Xu; Jian-Ping Wu; Wen-Cheng Li; Jia-Geng Zhu; Rui-Peng Jia
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-30       Impact factor: 4.553

4.  miR-297 acts as an oncogene by targeting GPC5 in lung adenocarcinoma.

Authors:  Yunchuan Sun; Jianyong Zhao; Xiaoming Yin; Xiangkun Yuan; Jianfei Guo; Jianqiang Bi
Journal:  Cell Prolif       Date:  2016-08-24       Impact factor: 6.831

5.  miR-873 induces lung adenocarcinoma cell proliferation and migration by targeting SRCIN1.

Authors:  Yushun Gao; Qi Xue; Dali Wang; Minjun Du; Yanjiao Zhang; Shugeng Gao
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

6.  Genome-wide miRNA response to anacardic acid in breast cancer cells.

Authors:  David J Schultz; Penn Muluhngwi; Negin Alizadeh-Rad; Madelyn A Green; Eric C Rouchka; Sabine J Waigel; Carolyn M Klinge
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

7.  Predictive microRNAs for lymph node metastasis in endoscopically resectable submucosal colorectal cancer.

Authors:  Chan Kwon Jung; Seung-Hyun Jung; Seon-Hee Yim; Ji-Han Jung; Hyun Joo Choi; Won-Kyung Kang; Sung-Won Park; Seong-Taek Oh; Jun-Gi Kim; Sug Hyung Lee; Yeun-Jun Chung
Journal:  Oncotarget       Date:  2016-05-31

8.  Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo.

Authors:  Xiangxiang Hu; Si Shi; Huan Wang; Xiaochen Yu; Qian Wang; Shanshan Jiang; Dianwen Ju; Li Ye; Meiqing Feng
Journal:  Sci Rep       Date:  2017-07-04       Impact factor: 4.379

Review 9.  MicroRNAs associated with therapy of non-small cell lung cancer.

Authors:  Junmi Lu; Yuting Zhan; Juan Feng; Jiadi Luo; Songqing Fan
Journal:  Int J Biol Sci       Date:  2018-03-10       Impact factor: 6.580

10.  MiR-338 regulates NFATc1 expression and inhibits the proliferation and epithelial-mesenchymal transition of human non-small-cell lung cancer cells.

Authors:  Wei He; Jibin Lu
Journal:  Mol Genet Genomic Med       Date:  2019-12-11       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.